Last updated on October 2014

A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza


Brief description of study

A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza

Detailed Study Description

This 2-arm study will investigate the safety and tolerability of twice daily con ventional and double dose Tamiflu (oseltamivir) for the treatment of influenza i n immunocompromised patients. Eligible immunocompromised patients with laborator y-confirmed influenza will be randomized to receive either conventional dose (30 mg-75mg twice daily po, depending on age and weight) or double dose (60mg-150mg twice daily po depending on age and weight) Tamiflu for 10 days. Nasal and throa t swabs will be taken, and safety evaluations made, at intervals during the stud y. The anticipated time on study medication is 10 days and the anticipated time on study is 40 days.

Clinical Study Identifier: TX139364

Contact Investigators or Research Sites near you

Start Over

Sharon Porth

University of South Florida - Tampa General Hospital
Tampa, FL USA
  Connect »